CL2013000655A1 - Compuestos derivados de fenoxidihidrobenzoxatiazepinas, moduladores de receptores ampa; composicion farmaceutica; procedimiento para preparalos; compuestos intermediarios; y su uso para el tratamiento o prevencion de trastornos mnemocognitivos asociados a la edad, sindromes ansiosos o depresivos y alzheimer, entre otras enfermedades. - Google Patents

Compuestos derivados de fenoxidihidrobenzoxatiazepinas, moduladores de receptores ampa; composicion farmaceutica; procedimiento para preparalos; compuestos intermediarios; y su uso para el tratamiento o prevencion de trastornos mnemocognitivos asociados a la edad, sindromes ansiosos o depresivos y alzheimer, entre otras enfermedades.

Info

Publication number
CL2013000655A1
CL2013000655A1 CL2013000655A CL2013000655A CL2013000655A1 CL 2013000655 A1 CL2013000655 A1 CL 2013000655A1 CL 2013000655 A CL2013000655 A CL 2013000655A CL 2013000655 A CL2013000655 A CL 2013000655A CL 2013000655 A1 CL2013000655 A1 CL 2013000655A1
Authority
CL
Chile
Prior art keywords
compounds
dihydrobenzoxathiazepines
anxious
alzheimer
phenoxy
Prior art date
Application number
CL2013000655A
Other languages
English (en)
Inventor
Alexis Cordi
Patrice Desos
Pierre Lestage
Laurence Danober
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43067253&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013000655(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of CL2013000655A1 publication Critical patent/CL2013000655A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D291/00Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/08Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D419/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D419/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
CL2013000655A 2010-09-16 2013-03-08 Compuestos derivados de fenoxidihidrobenzoxatiazepinas, moduladores de receptores ampa; composicion farmaceutica; procedimiento para preparalos; compuestos intermediarios; y su uso para el tratamiento o prevencion de trastornos mnemocognitivos asociados a la edad, sindromes ansiosos o depresivos y alzheimer, entre otras enfermedades. CL2013000655A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1003683A FR2964969B1 (fr) 2010-09-16 2010-09-16 Nouveaux derives dihydrobenzoxathiazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
CL2013000655A1 true CL2013000655A1 (es) 2013-08-09

Family

ID=43067253

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013000655A CL2013000655A1 (es) 2010-09-16 2013-03-08 Compuestos derivados de fenoxidihidrobenzoxatiazepinas, moduladores de receptores ampa; composicion farmaceutica; procedimiento para preparalos; compuestos intermediarios; y su uso para el tratamiento o prevencion de trastornos mnemocognitivos asociados a la edad, sindromes ansiosos o depresivos y alzheimer, entre otras enfermedades.

Country Status (40)

Country Link
US (1) US8569285B2 (es)
EP (1) EP2431360B1 (es)
JP (1) JP2013537216A (es)
KR (1) KR20130054438A (es)
CN (1) CN103153973A (es)
AP (1) AP2013006793A0 (es)
AR (1) AR082973A1 (es)
AU (1) AU2011213898A1 (es)
BR (1) BR112013005967A2 (es)
CA (1) CA2752131C (es)
CL (1) CL2013000655A1 (es)
CO (1) CO6680709A2 (es)
CR (1) CR20130105A (es)
CU (1) CU20130037A7 (es)
CY (1) CY1114110T1 (es)
DK (1) DK2431360T3 (es)
EA (1) EA201300340A1 (es)
EC (1) ECSP13012489A (es)
ES (1) ES2421504T3 (es)
FR (1) FR2964969B1 (es)
GE (1) GEP20156247B (es)
GT (1) GT201300067A (es)
HR (1) HRP20130505T1 (es)
IL (1) IL225209A0 (es)
MA (1) MA34529B1 (es)
ME (1) ME01524B (es)
MX (1) MX2013002892A (es)
NI (1) NI201300028A (es)
PE (1) PE20131342A1 (es)
PL (1) PL2431360T3 (es)
PT (1) PT2431360E (es)
RS (1) RS52835B (es)
SA (1) SA111320755B1 (es)
SG (1) SG188380A1 (es)
SI (1) SI2431360T1 (es)
TW (1) TWI421080B (es)
UA (1) UA105320C2 (es)
UY (1) UY33574A (es)
WO (1) WO2012035216A1 (es)
ZA (1) ZA201106353B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111559990B (zh) * 2020-05-29 2021-03-09 四川大学华西医院 一种小分子噁噻嗪类衍生物及其应用
CN111518058B (zh) * 2020-05-29 2021-03-09 四川大学华西医院 一种噁噻嗪类化合物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2214405C2 (ru) * 1998-02-18 2003-10-20 НьюроСёрч А/С Новые соединения и их применение в качестве положительных модуляторов амра-рецепторов
TWI232863B (en) * 2001-06-11 2005-05-21 Akzo Nobel Nv Benzoxazepine derivatives
MXPA03011562A (es) * 2001-06-14 2004-03-18 Akzo Nobel Nv Derivados de (pirido/tieno)-(f)-oxazepin-5-ona como moduladores positivos del receptor ampa.
FR2856064B1 (fr) * 2003-06-13 2005-08-19 Servier Lab Nouveaux derives de benzothiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
TW200714597A (en) * 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
HRP20130505T1 (hr) 2013-07-31
AP2013006793A0 (en) 2013-04-30
TW201212921A (en) 2012-04-01
ECSP13012489A (es) 2013-04-30
WO2012035216A1 (fr) 2012-03-22
BR112013005967A2 (pt) 2016-05-03
ME01524B (me) 2014-04-20
ES2421504T3 (es) 2013-09-03
CU20130037A7 (es) 2013-05-31
UA105320C2 (ru) 2014-04-25
CR20130105A (es) 2013-05-16
NI201300028A (es) 2014-01-07
JP2013537216A (ja) 2013-09-30
ZA201106353B (en) 2012-05-30
CO6680709A2 (es) 2013-05-31
SI2431360T1 (sl) 2013-07-31
FR2964969A1 (fr) 2012-03-23
CA2752131A1 (fr) 2012-03-16
US20120071462A1 (en) 2012-03-22
SG188380A1 (en) 2013-04-30
CY1114110T1 (el) 2016-07-27
PL2431360T3 (pl) 2013-08-30
EP2431360B1 (fr) 2013-04-17
CN103153973A (zh) 2013-06-12
UY33574A (es) 2012-03-30
EA201300340A1 (ru) 2013-08-30
EP2431360A1 (fr) 2012-03-21
SA111320755B1 (ar) 2013-11-10
PE20131342A1 (es) 2013-11-28
GEP20156247B (en) 2015-02-10
CA2752131C (fr) 2014-04-22
KR20130054438A (ko) 2013-05-24
DK2431360T3 (da) 2013-07-22
AU2011213898A1 (en) 2012-04-05
IL225209A0 (en) 2013-06-27
PT2431360E (pt) 2013-05-14
FR2964969B1 (fr) 2012-08-24
RS52835B (en) 2013-10-31
GT201300067A (es) 2014-07-08
AR082973A1 (es) 2013-01-23
MX2013002892A (es) 2013-04-10
MA34529B1 (fr) 2013-09-02
US8569285B2 (en) 2013-10-29
TWI421080B (zh) 2014-01-01

Similar Documents

Publication Publication Date Title
CL2014000806A1 (es) Compuestos derivados de 1-arilcarbonil-4-oxi-piperidino; composicion farmaceutica que los comprende; uso para la prevencion o el tratamiento de enfermedades neurodegenerativas tales como enfermedad de alzheimer, enfermedad de parkinson, enfermedad de huntington o esclerosis multiple.
BR112013004766A2 (pt) 2-amino-quinolina-3-carboxamidas substituídas como moduladores de kcnq2/3
CR20130588A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
UY29079A1 (es) Acidos fenoxiacéticos sustituidos, composiciones que los contienen, procedimientos de preparación y aplicaciones
BR112012013431A2 (pt) composto, composição farmacêutica e seu uso
CL2008000198A1 (es) Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis.
BRPI1012116A2 (pt) composição farmacêutica para o tratamento de doenças cardíacas
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
BR112014010177A2 (pt) composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença
BR112012016853A2 (pt) "composições farmacêuticas para administração oral de peptídeos de insulina".
UY29223A1 (es) Ácidos fenoxiacéticos sustituidos, composiciones farmacéuticas que los contienen y procesos para su preparación
BR112014021531A2 (pt) composto, composição farmacêutica e usos dos mesmos
CL2013001073A1 (es) Compuestos derivados de 6-amino-nicotinamidas sustituidas, como moduladores de kcnq2/3; composicion farmaceutica que los comprende, util para el tratamiento y/o profilaxis de trastornos y/o enfermedades seleccionadas de dolor, epilepsia, ansiedad, enfermedades cognitivas, entre otras.
CL2007003733A1 (es) Compuestos derivados de indolin-2-ona, bencimidazol-2-ona y benzoxazol-2-ona, moduladores de serina palmitoiltransferasa; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 1 y 2, obesidad, aterosclerosis, hi
UY29839A1 (es) Ácidos fenoxiaceticos sustituidos, composiciones farmacéuticas conteniéndolos, procesos para su preparación y aplicaciones.
CL2007002288A1 (es) Compuestos derivados de imidazol-amina condensados, inhibidores de la beta-secretasa; proceso de preparacion; composicion farmaceutica, util para el tratamiento, prevencion o mejoramiento de enfermedades tales como enfermedad de alzheimer, deterioro
CL2014001838A1 (es) Compuestos derivados de fluormetil-5,6-dihidro-4h-[1,3]oxazin-2-ilamina, como inhibidores de la bace1; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de alzheimer, esclerosis lateral amiotrofica, cancer, enfermedades cardiovasculares y enfermedades gastrointestinales, entre otras.
BR112014001908A2 (pt) derivados aza heterocíclicos substituídos
EA201590562A1 (ru) Бензамиды
BR112014011981B8 (pt) Formulações farmacêuticas sólidas orais, seus processos de preparação e usos
CO7131369A2 (es) 5-amino[1,4]tiazinas como inhibidores de bace1
ECSP11010956A (es) Compuestos enlazados con azufre para el tratamiento de enfermedades y trastornos oftalmicos
BR112012032721A2 (pt) compostos heterocíclicos, sua preparação e sua aplicação terapêutica
BR112015004306A2 (pt) fluorometil-substituído pirrol carboxamidas